More Post from the Author
- Akemona to Power Upcoming Tokenized Offering for Industrialized Innovation Impact Portfolio I
- La vacunacin materna contra el VRS reduce el riesgo de hospitalizacin infantil en ms del 80%
- ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
- CGTN: Ako kultrne vmeny podporuj nsko-vietnamsk priatestvo
- Milliken & Company verffentlicht Nachhaltigkeitsbericht 2025
Vitrolife Group completes refinancing facility backed by leading Nordic Banks
GOTHENBURG, Sweden, July 1, 2025 /PRNewswire/ -- Vitrolife AB (publ) has today renewed and signed a loan agreement of EUR 300 million comprising of term loan and revolving credit facility. The term loan will be used to refinance existing debt and the revolving credit facility will be available for general corporate purposes.
The loan agreement is backed by leading Nordic banks, with Nordea and SEB renewing their commitments and AB Svensk Exportkredit joining as a new lender, underscoring the Vitrolife Group's strong credit profile and focus on export. The loan agreement has a tenor of three-years and includes two one-year extension options.
"We appreciate the support from our existing and new banking partners in connection with this refinancing. This successful transaction underlines the confidence in the Vitrolife Group," says Bronwyn Brophy O'Connor, CEO of the Vitrolife Group.
Gothenburg, 1 July 2025
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO
Contact:
Amelie Wilson, Investor relations, external corporate communications and executive support,[emailprotected]
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Vitrolife Group completes refinancing facility backed by leading Nordic Banks |
SOURCE Vitrolife AB (publ)

More Post from the Author
- Akemona to Power Upcoming Tokenized Offering for Industrialized Innovation Impact Portfolio I
- La vacunacin materna contra el VRS reduce el riesgo de hospitalizacin infantil en ms del 80%
- ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
- CGTN: Ako kultrne vmeny podporuj nsko-vietnamsk priatestvo
- Milliken & Company verffentlicht Nachhaltigkeitsbericht 2025
